- /
- Supported exchanges
- / US
- / CVRX.NASDAQ
CVRx Inc (CVRX NASDAQ) stock market data APIs
CVRx Inc Financial Data Overview
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with CVRx Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get CVRx Inc data using free add-ons & libraries
Get CVRx Inc Fundamental Data
CVRx Inc Fundamental data includes:
- Net Revenue: 56 651 K
- EBITDA: -50 509 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-01-22
- EPS/Forecast: -0.4446
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CVRx Inc News
New
CVRx sees Q1 revenue in the range of $14.7M to $14.8M
* CVRx (CVRX [https://seekingalpha.com/symbol/CVRX]) on Monday said total revenue for the first quarter of 2026 is expected to be in the range of $14.7 million to $14.8 million compared to revenue f...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX). Such investors are advise...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX). Such investors are advised to...
CVRx outlines $63M-$67M 2026 revenue target as Barostim adoption accelerates with new CPT code
Earnings Call Insights: CVRx (CVRX) Q4 2025 MANAGEMENT VIEW * Kevin Hykes, President and CEO, highlighted fourth quarter revenue of $16 million and full year revenue of $56.7 million, noting "grow...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.